Table 2 Clinical characteristics of the replication cohort. Values represent median ± standard deviation
Replication cohort | All patients (n=23) | Crohn’s disease (n=14) | Ulcerative colitis (n=9) | Range | ||
|---|---|---|---|---|---|---|
Age (y) | 37.1 ± 11.9 | 35.0 ± 12.1 | 40.8 ± 11.5 | 18–54 | ||
BMI | 23.9 ± 4.2 | 23.9 ± 4.3 | 24.0 ± 4.4 | 18.7–32.1 | ||
Female sex, n (%) | 11 (47.8%) | 6 (42.8%) | 5 (55.6%) | Â | ||
Time since diagnosis, y | 5.0 ± 7 | 5.8 ± 9 | 3.8 ± 5 | 0–28 | ||
Smokers, n (%) | 7 (30.4%) | 7 (50%) | 0 | Â | ||
Prednisolone >20mg/day, n (%) | 6 (26.1%) | 4 (28.6%) | 2 (22.2%) | Â | ||
Budesonide, n (%) | 5 (21.7%) | 4 (28.6%) | 1 (11.1%) | Â | ||
Thiopurines, n (%) | 6 (26.1%) | 3 (21.4%) | 3 (33.3%) | Â | ||
Mesalamine therapy, n (%) | 9 (39.1%) | 4 (28.6%) | 5 (55.6%) | Â | ||
Clinical remission at week 14, n (%) | Â | 8 (57.1%) | 3 (33.3%) | Â | ||
Remitters (R)/non-remitters (NR) | Â | R | NR | R | NR | Â |
C-reactive protein, baseline |  | 5.1±8.25 | 7.7±19.7 | 2.4±1.3 | 8.7±4.5 |  |
C-reactive protein, week 2 |  | 1.1±2.1 | 3.3±4.7 | 1±0.1 | 3.3±4.7 |  |
C-reactive protein, week 6 |  | 2.7±3.7 | 4.2±3.8 | 2.2±1.9 | 3.6±4.4 |  |
C-reactive protein, week 14 |  | 3±4.2 | 5±3.7 | 15.5±20.6 | 4.8±11.9 |  |
HBI/pMAYO score, baseline |  | 9±4.1 | 7.5±2.6 | 5±0 | 6±1.6 |  |
HBI/pMAYO score, week 2 |  | 5±3.0 | 5.5±0.8 | 4.5±0.7 | 5±2.3 |  |
HBI/pMAYO score, week 6 |  | 2±2.4 | 6±1.4 | 2±1.4 | 5±1.1 |  |
HBI/pMAYO score, week 14 |  | 0.5±1.5 | 5±0.9 | 2±0 | 6±0.5 |  |